Xoma Technology Ltd.
17 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
8
Ending by 2030
Jun 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 27, 2026The maintenance fee for Method of Increasing the Ratio of Effector T Cells to Regulatory T Cells in a Tumor by Administering to a Subject a Tgf-Beta Inhibitor and a PD-1 Antibody (US 11,685,775) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
- 1 fee due Jan 23, 2027The maintenance fee for Nucleic Acids Encoding, and Methods of Producing, Antibodies Specific for Transforming Growth Factor (TGF)-Beta (US 10,358,486) comes due Jan 23, 2027. Unpaid by Jul 23, 2027, it lapses early.
- 1 fee due Feb 11, 2027The maintenance fee for Methods and materials for targeted mutagenesis (US 9,102,711) comes due Feb 11, 2027. Unpaid by Aug 11, 2027, it lapses early.
- 1 fee due Mar 29, 2027The maintenance fee for Antibodies specific for TGF-β and methods of treatment thereof (US 9,145,458) comes due Mar 29, 2027. Unpaid by Sep 29, 2027, it lapses early.
Recent changes
- 1 term has ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,943,344 | Hepatocyte growth factor (HGF) binding proteins In force · From the USPTO record | In force | From the USPTO record | |
| US 8,273,355 | Hepatocyte growth factor (HGF) binding proteins In force · From the USPTO record | In force | From the USPTO record | |
| US 9,006,398 | EPHB3-SPECIFIC Antibody and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 9,541,004 | Antagonist Antibodies Against EPHB3 In force · High confidence | In force | High confidence | |
| US 7,649,083 | Hepatocyte growth factor (HGF) binding antibody In force · From the USPTO record | In force | From the USPTO record | |
| US 8,961,969 | Antagonist Antibodies Against EPHB3 In force · Medium confidence | In force | Medium confidence | |
| US 9,102,711 | Methods and materials for targeted mutagenesis In force · From the USPTO record | In force | From the USPTO record | |
| US 8,652,469 | M-CSF-specific monoclonal antibody and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,725,510 | Novel Modulators In force · High confidence | In force | High confidence | |
| US 9,944,698 | Modulators In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 20: 17 patents in force now held by others · 32 lapsed for an unpaid fee · 61 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
14 abandoned · 26 no status recorded